Inhibition of CEACAM1 expression in cytokine-activated neutrophils using JAK inhibitors

BMC Immunol. 2024 Oct 1;25(1):63. doi: 10.1186/s12865-024-00656-6.

Abstract

Objectives: Carcinoembryonic-antigen-related cell-adhesion molecule 1 (CEACAM1) is an adhesion molecule that acts as a coinhibitory receptor in the immune system. We previously demonstrated that CEACAM1 is predominantly expressed on peripheral blood neutrophils in patients with RA. The aim of the present study was to investigate the effects of Janus kinase inhibitors (JAKi) on cytokine-activated human neutrophils and CEACAM1 expression.

Methods: Peripheral blood neutrophils were obtained from healthy subjects. Isolated neutrophils were stimulated with tumor necrosis factor-alpha (TNF-α) or granulocyte-macrophage colony-stimulating factor (GM-CSF) in the presence or absence of JAKi. The expression of CEACAM1 in peripheral blood neutrophils was analyzed by flow cytometry. Protein phosphorylation of signal transducer and activator of transcription (STAT)1, STAT3, and STAT5 was assessed by western blot using phospho-specific antibodies.

Results: We found that TNF-α-induced CEACAM1 expression was marginally suppressed after pretreatment with pan-JAK inhibitor, tofacitinib. Moreover, TNF-α induced STAT1 and STAT3 phosphorylation at the late stimulation phase (4 to 16 h). The expressions of CEACAM1 on neutrophils were markedly up-regulated by GM-CSF not by interleukin (IL)-6 stimulation. All JAKi inhibited GM-CSF-induced CEACAM1 expressions on neutrophils, however, the inhibitory effects of baricitinib were larger compared to those of tofacitinib or filgotinib. Moreover, CEACAM1 was marginally upregulated in interferon (IFN)-γ stimulated neutrophils. Similarly, JAKi inhibited IFN-γ-induced CEACAM1 expressions on neutrophils.

Conclusions: We demonstrated that JAKi prevent GM-CSF-induced CEACAM1 expression in neutrophils, and JAKi-induced inhibition depends on their selectivity against JAK isoforms. These findings suggest that JAKi can modulate the expression of CEACAM1 in cytokine-activated neutrophils, thereby limiting their activation.

Keywords: Carcinoembryonic-antigen-related cell-adhesion molecule 1; Granulocyte-macrophage colony-stimulating factor neutrophils; Janus kinase inhibitors; Rheumatoid arthritis; Tumor necrosis factor-alpha.

MeSH terms

  • Antigens, CD* / metabolism
  • Cell Adhesion Molecules* / metabolism
  • Cytokines / metabolism
  • Granulocyte-Macrophage Colony-Stimulating Factor* / metabolism
  • Humans
  • Janus Kinase Inhibitors* / pharmacology
  • Neutrophil Activation / drug effects
  • Neutrophils* / drug effects
  • Neutrophils* / immunology
  • Neutrophils* / metabolism
  • Phosphorylation / drug effects
  • Piperidines / pharmacology
  • Pyrimidines* / pharmacology
  • Pyrroles / pharmacology
  • Signal Transduction / drug effects
  • Tumor Necrosis Factor-alpha* / metabolism

Substances

  • CD66 antigens
  • Cell Adhesion Molecules
  • Antigens, CD
  • Pyrimidines
  • Janus Kinase Inhibitors
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Tumor Necrosis Factor-alpha
  • tofacitinib
  • Piperidines
  • Pyrroles
  • Cytokines